Literature DB >> 21281558

A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia.

Andreas Reif1, Martin Schecklmann, Elisa Eirich, Christian P Jacob, Tomasz A Jarczok, Sarah Kittel-Schneider, Klaus-Peter Lesch, Andreas J Fallgatter, Ann-Christine Ehlis.   

Abstract

Cognitive deficits in tasks involving the prefrontal cortex such as working memory or verbal fluency are a key component of schizophrenia. This led to the hypofrontality hypothesis of schizophrenia, which is widely accepted even though molecular underpinnings are elusive. While disturbances of glutamatergic neurotransmission might play a role, other components have rarely been investigated. Recently, the promoter region of nitric oxide (NO) synthase-I (NOS-I, encoded by the gene NOS1), impacting on prefrontal glutamate transmission, has repeatedly been associated with schizophrenia. We thus tested whether an associated schizophrenia risk variant (rs41279104), leading to reduced expression of the transcript, influences prefrontal brain functioning. Forty-three patients suffering from chronic schizophrenia and 44 controls were genotyped for NOS1 rs41279104 and investigated by means of functional near-infrared spectroscopy (fNIRS), while completing a working-memory task (2-back test) and a verbal fluency test (VFT). After matching for genotype, behavioural and brain activation data of 26 patients and 28 comparable controls were correlated to rs41279104. Healthy controls showed significant activation of large parts of the lateral prefrontal cortex during both tasks, whereas task-related changes in oxygenation were significantly reduced in patients. Schizophrenia patients also performed worse in both tasks. The NOS1 schizophrenia risk genotype rs41279104 AA/AG was associated with slower reaction time in the 2-back task, as well as with reduced right-hemispheric activation of the frontal cortex for VFT in patients only. Our fNIRS data extend previous studies suggesting disturbed prefrontal functioning in schizophrenia and suggest that genetic variation of NOS1 has a role in cognitive dysfunction, probably by mediating glutamatergic tone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281558     DOI: 10.1017/S1461145710001677

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  10 in total

1.  MAP1B and NOS1 genes are associated with working memory in youths with attention-deficit/hyperactivity disorder.

Authors:  Angélica Salatino-Oliveira; Flávia Wagner; Glaucia C Akutagava-Martins; Estela M Bruxel; Júlia P Genro; Cristian Zeni; Christian Kieling; Guilherme V Polanczyk; Luis A Rohde; Mara H Hutz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-02       Impact factor: 5.270

2.  An investigation of hypofrontality in an animal model of schizophrenia using real-time microelectrochemical sensors for glucose, oxygen, and nitric oxide.

Authors:  Niall J Finnerty; Fiachra B Bolger; Erik Pålsson; John P Lowry
Journal:  ACS Chem Neurosci       Date:  2013-04-25       Impact factor: 4.418

Review 3.  Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.

Authors:  Regina F Nasyrova; Dmitriy V Ivashchenko; Mikhail V Ivanov; Nikolay G Neznanov
Journal:  Front Physiol       Date:  2015-05-11       Impact factor: 4.566

4.  Common and Rare Genetic Risk Factors Converge in Protein Interaction Networks Underlying Schizophrenia.

Authors:  Xiao Chang; Leandro de Araujo Lima; Yichuan Liu; Jin Li; Qingqin Li; Patrick M A Sleiman; Hakon Hakonarson
Journal:  Front Genet       Date:  2018-09-28       Impact factor: 4.599

Review 5.  Genetic Factors of Nitric Oxide's System in Psychoneurologic Disorders.

Authors:  Regina F Nasyrova; Polina V Moskaleva; Elena E Vaiman; Natalya A Shnayder; Nataliya L Blatt; Albert A Rizvanov
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923

Review 6.  Early-stage visual perception impairment in schizophrenia, bottom-up and back again.

Authors:  Petr Adámek; Veronika Langová; Jiří Horáček
Journal:  Schizophrenia (Heidelb)       Date:  2022-03-21

7.  Assessment of DDAH1 and DDAH2 Contributions to Psychiatric Disorders via In Silico Methods.

Authors:  Alena A Kozlova; Anastasia N Vaganova; Roman N Rodionov; Raul R Gainetdinov; Nadine Bernhardt
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

8.  Glutamate neurocircuitry: theoretical underpinnings in schizophrenia.

Authors:  Thomas L Schwartz; Shilpa Sachdeva; Stephen M Stahl
Journal:  Front Pharmacol       Date:  2012-11-26       Impact factor: 5.810

9.  A novel approach to probabilistic biomarker-based classification using functional near-infrared spectroscopy.

Authors:  Tim Hahn; Andre F Marquand; Michael M Plichta; Ann-Christine Ehlis; Martin W Schecklmann; Thomas Dresler; Tomasz A Jarczok; Elisa Eirich; Christine Leonhard; Andreas Reif; Klaus-Peter Lesch; Michael J Brammer; Janaina Mourao-Miranda; Andreas J Fallgatter
Journal:  Hum Brain Mapp       Date:  2012-01-16       Impact factor: 5.038

Review 10.  Near-infrared spectroscopy in schizophrenia: a possible biomarker for predicting clinical outcome and treatment response.

Authors:  Shinsuke Koike; Yukika Nishimura; Ryu Takizawa; Noriaki Yahata; Kiyoto Kasai
Journal:  Front Psychiatry       Date:  2013-11-14       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.